Refereed Journals


[232] Structure−Activity Relationship and in Vitro Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) Studies of N‑aryl 3‑Trifluoromethyl Pyrido[1,2‑a]benzimidazoles that Are Efficacious in a Mouse Model of Schistosomiasis.  G. Mayoka, J. Keiser, C. Häberli and K. Chibale* ACS Infect. Dis. 2019, 5, 418−429
[231] Antimalarial Pyrido[1,2‑a]benzimidazole Derivatives with Mannich Base Side Chains: Synthesis, Pharmacological Evaluation, and Reactive Metabolite Trapping Studies.   J. Okombo, and K. Chibale* ACS Infect. Dis. 2019, 5, 372−384
[230] Multistage Antiplasmodium Activity of Astemizole Analogues and Inhibition of Hemozoin Formation as a Contributor to Their Mode of Action.  M. Kumar, J. Okombo, D. Mambwe, D. Taylor, N. Lawrence, J. Reader, M. van der Watt, D. Fontinha, M. Sanches-Vaz, B. C. Bezuidenhout, S. B Lauterbach, D. Liebenberg, L.-M. Birkholtz, T.L. Coetzer, M. Prudêncio, T. J. Egan, S. Wittlin and K. Chibale* ACS Infect. Dis. 2019, 5, 303−315
[229] Structure−Activity Relationship Studies and Plasmodium Life Cycle Profiling Identifies Pan-Active N‑Aryl-3-trifluoromethyl Pyrido[1,2‑a]benzimidazoles Which Are Efficacious in an in Vivo
Mouse Model of Malaria.  G. Mayoka, M. Njoroge, J. Okombo, L. Gibhard, M. Sanches-Vaz, D. Fontinha,L.-M. Birkholtz, J. Reader, M. van der Watt, T. L. Coetzer, S. Lauterbach, A. Churchyard, B. Bezuidenhout, T. J. Egan, C.Yeates, S. Wittlin, M. Prudêncio, and K. Chibale* J. Med. Chem. 2019, 62, 1022−1035
[228] Structure-activity relationship studies of antiplasmodial cyclometallated ruthenium(II), rhodium(III) and iridium(III) complexes of 2-phenylbenzimidazoles.  L. Rylands, A. Welsh, K. Maepa, T. Stringer, D. Taylor, K. Chibale and G. S. Smith∗ Eur. J. Med. Chem, 2019, 161, 11–21